KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. PMID 40467365 · Eur Urol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial. PMID 40460988 · Ann Oncol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma. PMID 40438087 · Liver Cancer · 2025-Oct The record describes a matching-adjusted indirect comparison (MAIC) of two separate trials. While it analyzes time-to-event data (OS, PFS) and involves drug interventions, it is not the primary report of a randomized trial. The required criteria of an 'original formal-result report of a randomized trial' is not met.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer. PMID 40434336 · J Perianesth Nurs · 2025-Oct The study is a randomized controlled trial in oncology (lung cancer surgery) with a drug intervention (ropivacaine and esketamine), but it is a perioperative analgesia study, not a definitive therapeutic trial evaluating a cancer-specific time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study. PMID 40412421 · Lancet Infect Dis · 2025-Oct 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia. PMID 40407269 · Leuk Lymphoma · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetics and Exposure-Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn's Disease. PMID 40401357 · J Clin Pharmacol · 2025-Oct The study is a pharmacokinetic and exposure-response analysis from a Phase III trial in Crohn's disease (inflammatory bowel disease), which is a non-oncology condition. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS) for a human malignant neoplasm.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. PMID 40393861 · Eur Urol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Underdiagnosis of positive resection margins and synchronous peritoneal metastases in locally advanced colon cancer: histopathological reassessment of primary resection in the COLOPEC trial. PMID 40374989 · Virchows Arch · 2025-Oct The report is a pathological analysis of the COLOPEC trial (which is a randomized trial with a drug intervention and time-to-event endpoints), but it is not the primary/definitive efficacy report of the trial itself. Furthermore, the explicit trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided metadata, which is a required criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS. PMID 40360369 · Clin Lymphoma Myeloma Leuk · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial. PMID 40348701 · Eur Urol · 2025-Oct The record describes a phase 3 randomized trial of a surgical technique (NeuroSAFE-guided vs standard RARP) for localized prostate cancer. While it meets criteria for oncology, human, randomized, and phase 3, it lacks a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR data, focusing instead on functional outcomes.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. PMID 40331064 · Liver Cancer · 2025-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 4 Figure · 10 Panel · risk visible
Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial. PMID 40289847 · Arthritis Rheumatol · 2025-Oct The study is a randomized controlled trial of a tumor necrosis factor inhibitor in rheumatoid arthritis, which is not an oncology/malignant neoplasm indication. Therefore, it does not meet the primary oncology eligibility criterion for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An Online Treatment Decision Aid for Men with Low-risk Prostate Cancer Eligible for Active Surveillance and Their Partners Increases the Uptake of Active Surveillance: The Navigate Randomised Controlled Trial. PMID 40222891 · Eur Urol Oncol · 2025-Oct The study is a randomized controlled trial in low-risk prostate cancer, but it evaluates a decision aid (non-drug intervention) and its primary endpoint is uptake of active surveillance (a categorical treatment choice), not a time-to-event efficacy endpoint like OS, PFS, or DFS. No Kaplan-Meier or hazard ratio results are reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. PMID 40222621 · J Hepatol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review. PMID 40192957 · Infection · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials. PMID 40147791 · J Hepatol · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Xanomeline-Trospium: A Novel Therapeutic for the Treatment of Schizophrenia. PMID 40145363 · Ann Pharmacother · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Complex, low-intensity, individualised naturalistic developmental behavioural intervention in toddlers and pre-schoolers with autism spectrum disorder: The multicentre, observer-blind, parallel-group randomised-controlled A-FFIP trial. PMID 40135359 · J Child Psychol Psychiatry · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fractional flow reserve or OCT to guide management of complex and noncomplex angiographically intermediate coronary stenosis. PMID 40107654 · Rev Esp Cardiol (Engl Ed) · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effectiveness comparison between ceftazidime-avibactam and carbapenem-based regimens in nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections. PMID 40059019 · J Microbiol Immunol Infect · 2025-Oct The study is a retrospective, observational, single-center study in infectious diseases (nosocomial bacteremia), not an oncology randomized controlled trial. It does not meet the required oncology, randomized, or Phase III criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships. PMID 40030121 · JCO Oncol Pract · 2025-Oct The record is a cross-sectional study analyzing conflicts of interest in Japanese cancer clinical trials. While it references Phase III randomized trials, the study itself is not an original report of a trial's efficacy results. It lacks any time-to-event efficacy endpoint and does not present drug intervention outcomes from a specific trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscopic suturing to prevent migration of esophageal fully covered self-expandable metal stents: a randomized controlled trial (with video). PMID 40024292 · Gastrointest Endosc · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Physical recovery after local resection of nonpedunculated rectal adenomas and T1 carcinomas: endoscopic submucosal dissection versus transanal minimally invasive surgery. PMID 39956469 · Gastrointest Endosc · 2025-Oct The study is excluded because it is not a drug intervention trial and does not have a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier analysis or hazard ratio. The primary endpoint is mean time to recovery, a functional outcome, not a survival endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment. PMID 39909280 · Clin Gastroenterol Hepatol · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Randomized comparison of precut papillotomy versus an endoscopic ultrasound-guided rendezvous procedure for difficult biliary access in malignant distal biliary obstruction. PMID 39799946 · Endoscopy · 2025-Oct The study is a randomized controlled trial in an oncology context, but it compares two procedural techniques (endoscopic interventions) and does not involve a drug-containing intervention. The primary and secondary outcomes are technical success, adverse events, procedure duration, and length of stay, which are not time-to-event efficacy endpoints (e.g., OS, PFS, DFS). Therefore, it does not meet the criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05). PMID 39727010 · Cancer Res Treat · 2025-Oct The record describes a randomized Phase III trial (PREMIER, KCSG GU16-05) evaluating pemetrexed maintenance vs. observation in advanced urothelial carcinoma, with PFS as primary and OS as secondary time-to-event endpoints, reporting HRs and KM data. All required criteria are explicitly established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 1 Figure · 2 Panel · risk not_visible
CAMONCO 2: Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life. PMID 39700437 · JCO Oncol Pract · 2025-Oct The trial is randomized and oncology-focused with a time-to-event endpoint (overall survival), but it lacks explicit confirmation of Phase III/IIIb or Phase II/III, and the intervention (Open Dialogue About Complementary Alternative Medicine) is not a pharmacologic drug intervention, which is required for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. PMID 39317633 · Eur Urol · 2025-Oct The record describes a final analysis of patient-reported outcomes (quality of life, pain deterioration, tolerability) from a Phase III randomized trial. While the trial itself meets oncology, human, randomized, phase, and drug-intervention criteria, the reported results are not for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and do not feature Kaplan-Meier or HR for efficacy. It is a secondary analysis focusing on PROs, not efficacy.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma. PMID 39257075 · J Chemother · 2025-Oct 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial. PMID 38913220 · Cardiovasc Drugs Ther · 2025-Oct 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effect of lobar versus sublobar video-assisted thoracoscopic surgery lung resection on patient quality of life. PMID 41376921 · J Thorac Dis · 2025-Nov-30 Study is a non-randomized, retrospective analysis of surgical procedures (lobectomy vs. sublobar resection) for lung cancer with a primary quality-of-life endpoint, not a randomized drug trial with a time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative effectiveness and safety of systemic therapies for treatment-naïve, PD-L1 expression <1% advanced NSCLC: a systematic review and network meta-analysis. PMID 41367554 · Transl Lung Cancer Res · 2025-Nov-30 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Role of fallopian tube and cervical canal occlusion in preventing intra-operative tumour spillage in early endometrial cancer- a pilot study. PMID 41318519 · World J Surg Oncol · 2025-Nov-29 The study is a pilot randomized trial of a surgical technique (cervical/tubal occlusion) to prevent tumor spillage in endometrial cancer, without a drug intervention, and does not report a time-to-event efficacy endpoint. It is not a Phase III or definitive randomized trial of a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials. PMID 41318485 · Arthritis Res Ther · 2025-Nov-29 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lidocaine versus sufentanil in patient-controlled intravenous analgesia after laparoscopic colorectal cancer surgery: a prospective, randomized, double-blind clinical trial. PMID 41318377 · BMC Anesthesiol · 2025-Nov-29 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Is there a difference in the postoperative quality of recovery and analgesia between erector spinae and serratus anterior plane blocks following modified radical mastectomy: a randomized controlled study. PMID 41315952 · BMC Anesthesiol · 2025-Nov-29 The study is a randomized controlled trial in oncology patients but compares two regional anesthesia techniques (erector spinae plane block vs. serratus anterior plane block) for postoperative analgesia and recovery quality. It is not a Phase III/IIIb or Phase II/III trial of a systemic drug intervention. The primary endpoint is a patient-reported quality of recovery score (QoR-40), not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of short-course durvalumab combined with dose-dense EC in the neoadjuvant setting for locally advanced luminal B/HER2(-) or triple-negative breast cancer. PMID 41316390 · Breast Cancer Res · 2025-Nov-28 The record describes a non-randomized, single-arm, Phase 1b/2 trial. The primary efficacy endpoint is pathological complete response (pCR), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for a randomized trial with a time-to-event primary/key secondary endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. PMID 41316297 · Respir Res · 2025-Nov-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Real-world efficacy of nanoliposomal irinotecan in patients with advanced pancreatic cancer. PMID 41316032 · BMC Cancer · 2025-Nov-28 The record is a Phase 4 observational, retrospective, non-randomized study. It does not meet the inclusion criteria for an original formal result of a human malignant-neoplasm Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors. PMID 41315323 · Sci Rep · 2025-Nov-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial. PMID 41315271 · Nat Commun · 2025-Nov-28 The report is a randomized, oncology trial with drug intervention and time-to-event efficacy (EFS), but it is explicitly described as a 'pilot trial' and lacks evidence of being Phase III/IIIb or Phase II/III, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysis. PMID 41314984 · J Immunother Cancer · 2025-Nov-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial. PMID 41314851 · BMJ Open · 2025-Nov-28 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT. PMID 41314669 · RMD Open · 2025-Nov-28 The study is excluded because it is not in an oncology population (axial spondyloarthritis) and does not have a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. PMID 41314667 · RMD Open · 2025-Nov-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Psychometric validation and meaningful change thresholds of the Skindex-10 questionnaire and 5-D Itch scale for assessing itch in patients with chronic kidney disease-associated pruritus. PMID 41307595 · J Patient Rep Outcomes · 2025-Nov-27 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term hormone therapy for perimenopausal and postmenopausal women. PMID 41307293 · Cochrane Database Syst Rev · 2025-Nov-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. PMID 40888723 · N Engl J Med · 2025-Nov-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. PMID 40834881 · Blood · 2025-Nov-27 The record describes a secondary biomarker subgroup analysis from a Phase III randomized trial in multiple myeloma, reporting time-to-event outcomes (OS) with HRs. However, it is not the primary efficacy report of the trial, and the specific drug intervention(s) are not detailed, making it ineligible as a primary drug efficacy report.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -